 SAN FRANCISCO and RADNOR, Pa., July 12, 2021 PRNewswire -- NRx Pharmaceuticals, Inc. NRx Nasdaq: NRXP and Quantum Leap Healthcare CollaborativeTM Quantum Leap have begun treating patients with inhaled ZYESAMIÔ Aviptadil, in the I-SPY COVID Trial NCT04488081, a phase 2 adaptive platform trial aimed at improving treatment for severely and critically ill COVID-19 patients. 